Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study

PURPOSE: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade. We conducted a phase 2 trial of PARPi olaparib and anti-PD-L1 durvalumab and collected paired fresh core biopsies and blood...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Lampert, Erika J., Zimmer, Alexandra, Padget, Michelle, Cimino-Mathews, Ashley, Nair, Jayakumar, Liu, Yingmiao, Swisher, Elizabeth M., Hodge, James W., Nixon, Andrew B., Nichols, Erin, Bagheri, Mohammad H., Levy, Elliott, Radke, Marc R., Lipkowitz, Stanley, Annunziata, Christina M., Taube, Janis M., Steinberg, Seth M., Lee, Jung-Min
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7442720/
https://ncbi.nlm.nih.gov/pubmed/32398324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0056
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items